Topic

 and can be reached at mrivers@mjhlifesciences.com.

Articles

Judith Kulich, principal, patient health and equity lead, ZS, and Nan Gu, associate principal, patient health and equity, ZS, discuss health equity in pharma, specifically racial biases, and how the industry can address access and inequities going forward. 

Health Equity in Pharma: Q&A with ZS

Ryan Moog is head of clinical trials at Datavant. 

The COVID-19 pandemic has exposed global health inequities and is driving life sciences companies to establish strategies and better leverage data to address systemic causes and improve equity in access to healthcare innovations, particularly in clinical trials.

Bridging the Health Equity Gap in Clinical Development

Pharm Exec spoke with the senior vice president and vice president and therapeutic area head of global medical, inflammation & representation in clinical research at Amgen about how important health equity is to the entire industry.

Building Up Health Equity: Q&A With Ian Thompson and Ponda Motsepe-Ditshego of Amgen

Director for Market Access and Pricing in Healthcare, Boston Consulting Group

BCG Henderson Institute Ambassador, Boston Consulting Group

Managing Director and Senior Partner, Boston Consulting Group

A survey of 18 biopharmas, measuring their scope and implementation across key health equity dimensions and activities, uncovers useful context as companies seek better alignment of these goals with overall strategy.

Clues on Equity Engagement Levels

Health disparities brought on by racial bias remain quite prevalent in areas such as drug access, use of diagnostics, and representation in clinical trials, but society-jarring events in recent years have sparked renewed efforts by industry to tackle these issues with tangible and hopeful gains.

Taking Steps to Right the Wrongs: The Impact of Racial Bias in Healthcare and Medicine

Dr. Arturo Loaiza-Bonilla, MD, is the co-founder and chief medical officer of Massive Bio.

Overcoming persistent barriers to health equity in oncology trials will require innovation and cooperation.

Health Equity Barriers in Oncology Trials

Michael Wong is an emeritus board member of the Harvard Business School Healthcare Alumni Association (HBSHAA).

Angie Lindsey, vice president of marketing, Fresenius Kabi USA shares 2023 strategies for talent management strategies in life sciences, specifically as it relates to sales and marketing. 

Talent Management Strategies for Sales and Marketing

Videos

This segment conveys the importance of decentralizing clinical trials to increase diversity and serve all types of people in the United States, as well as the industry.  In addition, it touches on the importance of having diverse investigators to help recruit and communicate with all types of people.

Clinical Trials and Representation

“The nuance of language, and culture, and understanding” — what happened to the diversity of agency creative directors in the past 30 years? Only about 20% of creative directors are women, and at last count, there are only ten Black executive creative directors in the entire advertising industry from big holding companies, one with a healthcare focus.

The Messenger Matters 

The importance of data analytics can not be understated when putting together inclusive workforces. Bringing in and retaining top talent across all races is of the utmost importance to benefit all stakeholders, especially the patients. You have to have the right people “in the room” representing our diverse population.

DE&I